Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial.

ABSTRACT:

Background

The efficacy and safety of conventional first-line chemotherapeutic regimens for the treatment of advanced biliary tract carcinomas (ABTCs) have been unsatisfactory.

Objectives

We aimed to explore alternative chemotherapeutic regimens capable of providing improved efficacy and fewer side-effects.

Design

Multicentre, randomised, phase II clinical trial.

Methods

Patients with unresectable advanced-stage tumors, or those who have developed recurrence or metastasis following initial radical surgery, between January 2021 and November 2022 were included. The participants were randomised to either a gemcitabine-cisplatin group (GC) or an albumin-paclitaxel-cisplatin group (NC). Progression-free survival (PFS) was the primary outcome, whereas overall surviva

SUBMITTER: Yang X 

PROVIDER: S-EPMC12357391 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature